Arlene O. Siefker-Radtke, MD

Articles

Dr Siefker-Radtke on the Safety of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

May 6th 2024

Arlene O. Siefker-Radtke, MD, discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer.

Dr Siefker-Radtke on the Efficacy of Erdafitinib vs Pembrolizumab in FGFR-Altered mUC

November 8th 2023

Arlene O. Siefker-Radtke, MD, discusses the efficacy of erdafitinib in patients with metastatic urothelial cancer with select FGFR alterations in the phase 3 THOR study.

Dr. Siefker-Radtke on Unmet Needs in Frontline Urothelial Cancer Treatment

November 14th 2022

Arlene O. Siefker-Radtke, MD, discusses key therapeutic developments aimed at addressing unmet needs in metastatic urothelial carcinoma treatment.

Dr. Siefker-Radtke on Erdafitinib in Urothelial Carcinoma

November 11th 2022

Arlene O. Siefker-Radtke, MD, discusses the use of erdafitinib in urothelial carcinoma.

Future Outlook on the Management of Metastatic Urothelial Cancer

December 15th 2021

Drs Arlene O. Siefker-Radtke and Scott T. Tagawa consider how the urology field will likely advance with more interest in genomic profiling in metastatic urothelial cancer and novel therapies in the pipeline.

Mitigating FGFR Inhibitor TRAEs in Metastatic Urothelial Cancer

December 15th 2021

An overview of adverse events commonly associated with FGFR-targeted therapies such as erdafitinib.

FGFR Inhibitors in Metastatic Urothelial Cancer and the Management of Ocular Toxicity

December 15th 2021

What oncologists need to know about the management of ocular toxicity for patients with metastatic urothelial cancer receiving FGFR-targeted therapy.

FGFR-Targeted Therapy for Metastatic Urothelial Cancer

December 6th 2021

Strategies that can be used to counsel patients on molecular testing for FGFR mutations and what to expect from treatment with erdafitinib.

Repeat Molecular Testing in Metastatic Urothelial Cancer

December 6th 2021

Current recommendations for repeat testing in patients with relapsed metastatic urothelial cancer.

Frontline Therapy for Metastatic Urothelial Cancer

December 1st 2021

Factors that impact the selection of immunotherapy vs chemotherapy for frontline metastatic urothelial cancer.

Treatment Planning for a Patient With Metastatic Urothelial Cancer

December 1st 2021

Drs Arlene O. Siefker-Radtke and Scott T. Tagawa explain how they would establish goals of therapy and a treatment algorithm for a patient who presents with metastatic urothelial cancer.

Genomic Profiling Assays in Metastatic Urothelial Cancer

November 24th 2021

The significance of using broad genomic profiling tests to help detect promising biomarkers in metastatic urothelial cancer.

Multidisciplinary Care in Metastatic Urothelial Cancer

November 24th 2021

An overview of the types of health care professionals who may help manage patients with metastatic urothelial cancer throughout their disease course.

Barriers to Molecular Testing in Metastatic Urothelial Cancer

November 17th 2021

A discussion on molecular testing in the community and recommendations that can address barriers.

Molecular Testing in Metastatic Urothelial Cancer During COVID-19

November 17th 2021

The impact of the COVID-19 pandemic on rates of molecular testing used by community oncologists who care for patients with urothelial cancer.

Testing for FGFR Mutations in Metastatic Urothelial Cancer

November 10th 2021

A discussion on current prognostic and predictive testing assays used to detect FGFR mutations in patients with metastatic urothelial cancer (mUC).

Dr. Siefker-Radtke on Bempegaldesleukin Plus Nivolumab in Urothelial Carcinoma

February 17th 2019

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of bempegaldesleukin plus nivolumab in the treatment of patients with metastatic urothelial carcinoma.

Dr. Siefker-Radtke on Next Steps With Erdafitinib in Bladder Cancer

August 31st 2018

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses next steps with erdafitinib in patients with bladder cancer.

Dr. Siefker-Radtke on the Treatment of FGFR-Altered Bladder Cancer

August 3rd 2018

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with bladder cancer who have fibroblast growth factor receptor (FGFR)-altered tumors.

Dr. Siefker-Radtke on the Phase II Study of Erdafitinib in Patients With Urothelial Carcinoma

June 29th 2018

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the phase II study of erdafitinib in patients with metastatic or unresectable urothelial carcinoma who have FGFR alterations.